ReproCELL Inc. AI Stock Analysis
Want to see JP:4978 full AI Analyst Report?
ReproCELL Inc. (4978) AI Stock Analysis
ReproCELL Inc.
(TSE/TYO:4978)
The overall score of 43 reflects a high-risk investment profile heavily weighted by poor operational profitability and negative cash flows. The most significant risks are the severe operational losses and unprofitability, which drag down both the technical momentum and valuation metrics. However, the company's pristine, zero-debt balance sheet serves as a critical stabilizing factor, preventing immediate liquidity risks and keeping the score from hitting the absolute minimum.
ReproCELL Inc. (4978) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 11.64B
- Dividend Yield
- ―
- Average Volume (3M)
- 654.41K
- Price to Earnings (P/E)
- -25.1
- Beta (1Y)
- 0.59
- Revenue Growth
- -8.23%
- EPS Growth
- -48.10%
- Country
- Japan
- Employees
- 101
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
ReproCELL Inc. Business Overview & Revenue Model
Company Description
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, inc...
ReproCELL Inc. Financial Statement Overview
Summary
Despite an exceptionally strong, debt-free balance sheet that minimizes immediate financial risk, operational performance is highly vulnerable. Recent results show a swing to deep net losses, declining revenues, and substantial cash burn.
Income Statement
25NegativeBalance Sheet
92Very PositiveCash Flow
20Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.30B | 2.23B | 2.98B | 2.43B | 2.95B | 2.23B |
| Gross Profit | 1.06B | 1.01B | 1.63B | 1.10B | 1.13B | 785.42M |
| EBITDA | -800.69M | -785.10M | -79.70M | -372.18M | -307.23M | -587.37M |
| Net Income | -436.88M | -591.69M | 103.25M | -31.41M | -305.31M | -575.10M |
Balance Sheet | ||||||
| Total Assets | 9.80B | 9.65B | 9.67B | 9.05B | 8.36B | 8.10B |
| Cash, Cash Equivalents and Short-Term Investments | 5.62B | 6.51B | 3.94B | 6.57B | 6.38B | 4.64B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 80.00M |
| Total Liabilities | 727.77M | 805.59M | 685.81M | 741.03M | 780.63M | 844.53M |
| Stockholders Equity | 9.07B | 8.85B | 8.98B | 8.31B | 7.58B | 7.25B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -481.75M | -80.40M | -182.89M | -290.92M | -289.65M |
| Operating Cash Flow | 0 | -383.53M | 6.29M | -11.45M | -140.53M | -246.24M |
| Investing Cash Flow | 0 | 57.94M | -796.00M | 404.42M | -1.09B | -2.14B |
| Financing Cash Flow | 0 | 0 | 680.11M | 544.05M | 482.87M | 2.38B |
ReproCELL Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4978, the sentiment is Negative. The current price of 109.00 is below the 20-day moving average (MA) of 118.05, below the 50-day MA of 130.16, and below the 200-day MA of 147.25, indicating a bearish trend. The MACD of -5.81 indicates Positive momentum. The RSI at 35.85 is Neutral, neither overbought nor oversold. The STOCH value of 35.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4978.
ReproCELL Inc. Peers Comparison
Overall Rating
- JP:497843Neutral
JP:777442Neutral
JP:459339Underperform
JP:777639Underperform
JP:459938Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4978 | 43Neutral | JPY 11.65B | -25.06 | ― | ― | -8.23% | -48.10% |
| JP:7774 | 42Neutral | JPY 26.52B | -73.78 | ― | ― | 17.05% | 10.47% |
| JP:4593 | 39Underperform | JPY 30.90B | -13.76 | ― | ― | -51.55% | 52.19% |
| JP:7776 | 39Underperform | JPY 6.70B | -5.83 | ― | ― | -49.43% | -3.77% |
| JP:4599 | 38Underperform | JPY 7.33B | -3.94 | ― | ― | ― | 4.85% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4978 | ReproCELL Inc. | 109.00 | -48.00 | -30.57% | |
| JP:4593 | Healios KK | 228.00 | -223.00 | -49.45% | |
| JP:4599 | StemRIM Inc. | 117.00 | -161.00 | -57.91% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 653.00 | 175.00 | 36.61% | |
| JP:7776 | CellSeed Inc. | 169.00 | -232.00 | -57.86% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 10, 2026